Zai Lab (NASDAQ:ZLAB) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline progress toward a more globally oriented pipeline while emphasizing that the company’s China commercial business remains a key source of stability and funding for research and development. Founder, CEO, and Chairperson Dr. Samantha Du said Zai Lab is “building a […]

Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a large, non-dilutive financing tied to its sickle cell disease launch plans during its fourth-quarter and full-year 2025 results call. New PKU program: BEAM-304 Chief Executive Officer John Evans said the company is expanding its liver franchise with BEAM-304, an in […]

Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a large, non-dilutive financing tied to its sickle cell disease launch plans during its fourth-quarter and full-year 2025 results call. New PKU program: BEAM-304 Chief Executive Officer John Evans said the company is expanding its liver franchise with BEAM-304, an in […]